Breaking News

Tweet TWEET

New Single-Use Pall® XRS 20 Bioreactor System Enhances Cell Culture Performance in Biotechnology Applications

  New Single-Use Pall® XRS 20 Bioreactor System Enhances Cell Culture
  Performance in Biotechnology Applications

Next-Generation ‘Rocker’ Bioreactor is Ideal for Suspension Cultures for Life
               Sciences Applications Up to Full GMP Production

Business Wire

PORT WASHINGTON, N.Y. -- March 22, 2013

Pall Corporation (NYSE:PLL), a global leader in filtration, separation and
purification, today introduced the XRS 20 Bioreactor System, a new bioreactor
with unique agitation properties that incorporates a single-use, easy-to-use
Allegro™ 3D biocontainer. This next generation ‘rocker’ bioreactor, designed
for cultivation of mammalian cells in suspension culture, is equally suitable
for applications ranging from general life sciences research to seed train
operations and full Good Manufacturing Practice (GMP) production at the
2-to-20 liter scale.

The Pall XRS 20 Bioreactor System's unique bi-axial agitation properties
improve cell culture perfor ...

The Pall XRS 20 Bioreactor System's unique bi-axial agitation properties
improve cell culture performance. (Photo: Business Wire)

The XRS 20 System’s unique bi-axial agitation promotes better mixing and
higher mass transfer, which expedites transport of nutrients and metabolites
in the cellular micro-environment. This allows cultures to reach higher
densities with overall greater viabilities, leading to significantly higher
protein expression levels.

To ensure operational simplicity, the system includes the following features:

  *Allegro XRS 20 biocontainer with integrated components (sensors, filters,
    drain and tubing sets) for rapid installation and efficient harvesting
  *Advanced XRS 20 controller with touchscreen interface for easy monitoring
    and control of process parameters

A fully enclosed XRS 20 platform with interlock provides operator safety while
protecting sensitive media components from light.

“The versatile, easy-to-use XRS 20 Bioreactor System combines
state-of-the-art, single-use technology with advanced controls and features
that improve cell culture performance,” said Ken Frank, President, Pall
BioPharmaceuticals.

To learn more about the XRS 20 Bioreactor System please visit
www.pall.com/bioreactors.

Pall Life Sciences

Pall Life Sciences provides cutting-edge products and services to meet the
demanding needs of customers discovering, developing and producing biotech
drugs, vaccines and classic pharmaceuticals. The company’s membranes and
membrane devices optimize detection and sample preparation in the drug
research, clinical diagnostics, genomics, and proteomics markets. Pall is a
leading provider of separation systems and single-use filtration and
purification technologies to pharmaceutical and biotechnology companies to
support faster development of new drugs and vaccines that are safer and
require less energy and water to produce. Pall technologies are also used in
clinical institutions and the food and beverage industries.

About Pall Corporation

Pall Corporation (NYSE:PLL) is a filtration, separation and purification
leader providing solutions to meet the critical fluid management needs of
customers across the broad spectrum of life sciences and industry. Pall works
with customers to advance health, safety and environmentally responsible
technologies. The Company’s engineered products enable process and product
innovation and minimize emissions and waste. Pall Corporation is an S&P 500
company serving customers worldwide. Pall has been named a “top green company”
by Newsweek magazine. To see how Pall is helping enable a greener, safer, more
sustainable future, follow us on Twitter @PallCorporation or visit
www.pall.com/green.

Photos/Multimedia Gallery Available:
http://www.businesswire.com/multimedia/home/20130322005743/en/

Multimedia
Available:http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50596286&lang=en

Contact:

Pall Corporation
Rebecca Kale
Senior Marketing Communications Manager
Telephone: +44 (0)2392 303733
email: rebecca_kale@europe.pall.com